SCD and liver cancer: In liver cancer cell lines, sorafenib reduces the expression of oncoprotein hepatitis B X-interacting protein (HBXIP), thereby inhibiting SCD activation induced by the transcription factor ZNF263, leading to the accumulation of free FAs and the occurrence of ferroptosis [205].